Annual Congress Vienna 2003

Saturday, 27.09.2003
Sunday, 28.09.2003
Monday, 29.09.2003
Tuesday, 30.09.2003
Wednesday, 01.10.2003

Citations should be made in the following way: Authors. Title. Eur Respir J 2003; 22: Suppl. 45, abstract number.

Material from 2003:

3196 Abstracts
374 Slide presentations

Material from 2003: Show

Clinical aspects of community-acquired pneumonia

Thematic Poster Session
Chairs: K. Dalhoff (Lubeck, Germany), W. Boersma (Oudorp, The Netherlands)

Download all media

Community-acquired pneumonia outbreaks control with azithromycin I. A. Gouchev, O. I. Klochkov (Smolensk, Russia)
Antibiotic susceptibility patterns of respiratory strains of Staphylococcus aureus in a Turkish university hospital U. Gonlugur, M. Z. Bakici, L. Ozdemir, I. Akkurt, S. Icagasioglu, F. Gultekin (Sivas, Turkey)
Antibiotic usage analysis of the community-acquired pneumonia at young patients from different social groups Y. M. Mostovoy, H. V. Demchuk (Vinnytsia, Ukraine)
Diagnostic value of serum soluble interleukin-2 receptor (SIL- 2R) and acute phase proteins levels (APP) in community acquired pneumonia A. M. V. Trailescu, O. I. Nicolaescu, F. Toparceanu (Bucharest, Romania)
The assessment of prognostic rules in patients with community-acquired pneumonia (CAP) L. V. Koukol, S. A. Pupyshev, A. V. Pupyshev, B. I. Gelzer, V. A. Kudryavceva (Vladivostok, Russia)
The influence of smoking habit in patients with community-acquired pneumonia (CAP) L. Nagorni Obradovic, D. Jovanovic, S. Popevic, A. Blanka, M. Velinovic, D. Pesut (Belgrade, Yugoslavia)
Analysis of hospital acquired infection of low respiratory tract by Klebsiella pneumoniael and Escherichia coli and antibiotic resistance Z. Tong, Z. Wang, C. Wang, Q. Wang (Beijing, China)
Communnity-acquired pneumonia admitted in a universitary hospital: etiological study of 21 months J. Blanquer, M. L. Briones, C. Gimeno, C. Muñoz, D. Blanquer, J. Marin (Valencia, Palma de Mallorca, Spain)
Diagnosis and treatment of community acquired pneumonia in Moscow City Emergency Hospital no. 11 L. B. Sokolova, I. V. Fedorova, E. I. Shmelev (Moscow, Russia)
Different factors have impact on severe pneumonia resolution and mortality after the initial treatment period V. Dudzevicius, A. Vitkauskiene, R. Sakalauskas (Kaunas, Lithuania)
Temporal trends in community acquired pneumonia in two Canadian teaching hospitals T. K. Marras, C. K. N. Chan (Toronto, Canada)
Community-acquired pneumonia Initial risk class and length of hospital stay Z. M. Lazic, L. A. Novkovic, S. D. Mojsilovic, Z. M. Djokic, O. M. Gajovic (Kragujevac, Yugoslavia)
Community-acquired pneumonia (CAP) in patients admitted to a central hospital: an 18 months retrospective study A. Oliveira, S. Moreira, S. Simoes, E. Pestana, G. Duarte, F. Dias (Lisbon, Portugal)
What is the value of multiple sputum cultures in the routine investigation of community acquired pneumonia (CAP)? J. La Forge, N. Lampron, J. Plante (Sainte-Foy, Canada)
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France L. Laforest, P. J. Souquet, S. S. Sen, D. D. Yin, Y. Pacheco, G. Pietri, C. Brambilla, E. Van Ganse (Lyon, Grenoble, France; New Jersey, United States Of America)
Telithromycin displays high clinical efficacy in outpatients with mild to moderate community-acquired pneumonia caused by atypical/intracellular pathogens L. M. Dunbar, C. Carbon, R. Nusrat (New Orleans, Bridgewater, United States Of America; Lausanne, Switzerland)
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) M. Zervos, C. Andrews, C. Knirsch, R. Swanson, P. de Caprariis, L. Mandell (Royal Oak, San Antonio, United States Of America; , ; Ontario, Canada)
Telithromycin is highly efficacious in the treatment of lower respiratory tract infections M. Zervos, M. Aubier, R. Nusrat (Royal Oak, Bridgewater, United States Of America; Paris, France)
The role of atypical pathogens in the respiratory failure caused by lower respiratory tract infections O. Biyikli, I. Altuglu, A. Baysak Alpaydin, B. Yildirim, F. Bacakoglu, A. Bilgic (Izmir, Turkey)
*Lower overall healthcare costs with telithromycin (TEL) versus* clarithromycin (CLA) in community-acquired pneumonia (CAP)** J. R. Chang, P. G. Davey, J. Stewart, C. V. Asche, R. B. Nieman (Bridgewater, United States Of America; Dundee, United Kingdom; Quebec, Canada)